Top 7 Highlights From the 2014 ASH Meeting

References:

1. Moskowitz CH et al. The Aethera Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma. 2014 American Society of Hematology Annual Meeting. Abstract 673.

2. Stewart AK et al. Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients (Pts) with Relapsed Multiple Myeloma: Interim Results from ASPIRE, a Randomized, Open-Label, Multicenter Phase 3 Study. 2014 American Society of Hematology Annual Meeting. Abstract 79.

3. Armand P et al. Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma - Preliminary Safety, Efficacy and Biomarker Results of a Phase I Study. 2014 American Society of Hematology Annual Meeting. Abstract 289.

4. Moskowitz CH et al. PD-1 Blockade with the Monoclonal Antibody Pembrolizumab (MK-3475) in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Preliminary Results from a Phase 1b Study (KEYNOTE-013). 2014 American Society of Hematology Annual Meeting. Abstract 290.

5. Stein EM et al. AG-221, an Oral, Selective, First-in-Class, Potent Inhibitor of the IDH2 Mutant Metabolic Enzyme, Induces Durable Remissions in a Phase I Study in Patients with IDH2 Mutation Positive Advanced Hematologic Malignancies ). 2014 American Society of Hematology Annual Meeting. Abstract 115.

6. Ravandi F et al. Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin Plus Cytarabine Versus Placebo Plus Cytarabine: Results of a Phase 3 Double-Blind Randomized Controlled Multinational Study (VALOR). 2014 American Society of Hematology Annual Meeting. Abstract LBA-6.

7. Goekbuget N et al. BLAST: A Confirmatory, Single-Arm, Phase 2 Study of Blinatumomab, a Bispecific T-Cell Engager (BiTE®) Antibody Construct, in Patients with Minimal Residual Disease B-Precursor Acute Lymphoblastic Leukemia (ALL). 2014 American Society of Hematology Annual Meeting. Abstract 379.

Slide 1: Adding Brentuximab Vedotin Post-Transplant Boosts Progression-Free Survival in Hodgkin Lymphoma-

Patients with Hodgkin lymphoma who received brentuximab vedotin as consolidation therapy after an autologous stem cell transplantation (ASCT) lived significantly longer and without disease progression compared with those who received ASCT alone. The median progression-free survival was 43 months in the brentuximab vedotin arm compared with 24 months in the control arm (hazard ratio = 0.57;

P

= .001). The estimated 2-year progression-free survival rate was 54%, and the estimated 2-year overall survival rate was 88%.

Image source: Craig H. Moskowitz, MD, Memorial Sloan Kettering Cancer Center, New York.

[1]